Vemurafenib acts as an aryl hydrocarbon receptor antagonist: Implications for inflammatory cutaneous adverse events

BACKGROUND: In recent years, the BRAF-inhibitor vemurafenib has been successfully established in the therapy of advanced melanoma. Despite its superior efficacy, the use of vemurafenib is limited by frequent inflammatory cutaneous adverse events that affect patients’ quality of life and may lead to...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Allergy
Main Authors: Hawerkamp, Heike C., Kislat, Andreas, Gerber, Peter A., Pollet, Marius, Rolfes, Katharina M., Soshilov, Anatoly A., Denison, Michael S., Momin, Afaque A., Arold, Stefan T., Datsi, Angeliki, Braun, Stephan A., Oláh, Péter, Lacouture, Mario E., Krutmann, Jean, Haarmann-Stemmann, Thomas, Homey, Bernhard, Meller, Stephan
Format: Artigo
Sprog:Inglês
Udgivet: 2019
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6911016/
https://ncbi.nlm.nih.gov/pubmed/31269229
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/all.13972
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker